Download PDF
Thromb Haemost 1995; 74(01): 106-110
DOI: 10.1055/s-0038-1642661
Symposium
Thrombolytic Therapy
Schattauer GmbH Stuttgart

Thrombolytic Therapy: Future Issues

M M Samama
Service d’Hématologie Biologique, Paris, France
,
J Acar
Service de Cardiologie, Hôpital Tenon, France
› Author Affiliations
Further Information

Publication History

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 The GUSTO angiographic investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary arteiy patency, ventricular function, and survival after myocardial infarction. New Engl J Med 1993; 329: 1615-1622
    CrossrefPubMedGoogle Scholar
  • 2 Topol EJ. Thrombolytic intervention. In Topol EJ. ed. Textbook of interventional cardiology Philadelphia Saunders 1989; 76-120
    PubMedGoogle Scholar
  • 3 Hennekens CH. Thrombolytic therapy: pre- and post-GISSI-2, ISI-3, and GUSTO-1. Clinical Cardiology 1994; 17: 115-117
    PubMedGoogle Scholar
  • 4 Bates ER, Topol E. Thrombolytic mortality trials. In: Thrombolysis and adjunctive therapy for acute myocardial infarction. Eric RBates. ed. Marcel Dekker, Inc; New York, Basel, Hong-Kong: 1993: 63-69
    Google Scholar
  • 5 Collen D. Towards improved thrombolytic therapy. Lancet 1993; 342: 34-36
    CrossrefPubMedGoogle Scholar
  • 6 The European Myocardial Infarctus project group (EMIP group)101. Policy board : D. Julian (London), J. Lubsen (Rotterdam), M. Samama (Paris), P. Sleight (Oxford UK), G. Tognoni (Milan), and N. Victor (Heidelberg, Germany). Prehospital thrombolytic therapy in pateints with suspected acute myocardial infarction New Engl J Med. 1993 329. 383-389
    PubMedGoogle Scholar
  • 7 Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF. Comparative thrombolytic properties of tissue-type plasminogen activator inhibitor-1 -resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72 (01) 98-104
    PubMedGoogle Scholar
  • 8 Neuhaus KL, von Essen R, Vogt A, Tebbe U, Rustige J, Wagner HJ, Appel KF, Stienen U, Konig R, Meyer-Sabellek W. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction : results of the Genman Recombinant Plasminogen Activator Study. J Am Coll Cardiol 1994; 24 (01) 55-60
    CrossrefPubMedGoogle Scholar
  • 9 Bergum PW, Gardell SJ. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. J Biol Chem 1992; 267: 17726-17731
    PubMedGoogle Scholar
  • 10 Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential. Blood 1994; 84 (03) 680-686
    PubMedGoogle Scholar
  • 11 Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-1853
    CrossrefPubMedGoogle Scholar
  • 12 Verstraete M. Combination of urokinase and alteplase in the treatment of myocardial infarction. The urokinase and alteplase in myocardial infarction collaborative group. The URALMI group Cor ArtDis 1991; 2: 225-235
    PubMedGoogle Scholar
  • 13 Topol EJ, Calif RM, George BS, Kerelakes DJ, Rothbaum D, Candela RJ, Abbotsmith CW, Pinkerton CA, Stump DC, Collen D, Lee KL, Pitt B, Kline EM, Boswick JM, O’Neill WW, Stack RS. TAMI Study group. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokianse in patients with acute myocardial infarction Circulation 1988; 77 (05) 1100-1107
    CrossrefPubMedGoogle Scholar
  • 14 Bode C, Meinhardt G, Runge MS, Freitag M, Nordt T, Arens M, Newell JB, Kiibler W, Haber E. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991; 84 (02) 805-813
    CrossrefPubMedGoogle Scholar
  • 15 Dewerchin M, Collen D. Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot specific monoclonal antibodies. Bioconjug Chem 1991; 2 (05) 293-300
    CrossrefPubMedGoogle Scholar
  • 16 Bode C, Leinhardt G, Runge MS, Freitag M, Nordt T, Arens M, Newell JB, Kiibler W, Haber E. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 1991; 84: 805-813
    CrossrefPubMedGoogle Scholar
  • 17 Robinson JH, Browne MJ, Carey JE, Chamberlain PD, Chapman CG, Cronk DW, Doss I, Entwisle C, Esmail AF, Kalinkdjian B, Lawrence GM P, McMurdo L, Mitchell D, Smith RA G, Wilson S. A recombinant, chimeric enzyme with a novel mechanism of action leading to greater potency and selectivity than tissue-type plasminogen activator. Circulation 1992; 86: 548-552
    CrossrefPubMedGoogle Scholar
  • 18 Underwood MJ, Pringle SW, de Bono DP. Reduction of thrombus formationin vivo using a thrombolytic agent targeted at damaged endothelial cells. Br J Surg 1992; 79: 915-917
    CrossrefPubMedGoogle Scholar
  • 19 More RS, Underwood MJ, de Bono DP. Targeting fibrinolytic agents to the vessel wall: a new therapeutic niche. Thromb Haemostas 1994; 1: 158-159
    PubMedGoogle Scholar
  • 20 Torchilum VP, Papisons PM, Omerthova N, Belyaen A, Petrov AD, Ragomov SE. Magnetically driven thrombolysis preparations containing immobilized SK-targeted transport and action. Haemostasis 1988; 18: 113-116
    PubMedGoogle Scholar
  • 21 Dawson KM, Cook A, Devine JM, Edwards RM, Hunter MG, Raper RH, Roberts G. Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents. J Biol Chem 1994; 269 (23) 15989-15992
    PubMedGoogle Scholar
  • 22 Ellis SG, Tcheng JE, Navetta FI. et al. Safety and antiplateletect of murine monoclonal antibody 7E3 Fac directed against platelet glycoprotein Ilb-IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis 1993; 4: 167-176
    CrossrefPubMedGoogle Scholar
  • 23 Kleiman NS, Ohman EM, Keriakes DJ, Ellis NS, Ohman EM, Weisman HF, Topol EJ. Profound platelet inactivation with 7E3 shortly after thrombolytic therapy for acute myocardial infarction: Preliminary results of the TAMI8 Trial. Circulation 1991; 84 Supp.II 522-522 (abst)
    PubMedGoogle Scholar
  • 24 The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein Ilb-IIIa receptor in high risk coronary angioplasty N Engl J Med 1993; 330: 956-961
    PubMedGoogle Scholar
  • 25 Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, De Grado WF, Thoolen MJ, Reilly TM. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb-IIIa receptor antagonist. Circularion 1994; 89 (01) 3-12
    PubMedGoogle Scholar
  • 26 Haskel EJ, Adams SP, Feigen LP, Saffitz JE, Gorczynski RJ, Sobel BE, Abendschein DR. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein Ilb-Illa receptor. Circulation 1989; 80: 1775-1782
    CrossrefPubMedGoogle Scholar
  • 27 Escudero C, Alavarez L, de Haro J, Gonzalez J, Alvarez MV, Millian I, Jorge-Herrero E, Castillo-Olivares JL. Prevention of arterial thrombosis by a monoclonal antibody against to 100 to 109 amino acid sequencer stretch of the beta-subunit of the human platelet fibrinogen receptor: A comparative study with low dose aspirin. J Am Coll Cardiol 1994; 23: 483-486
    CrossrefPubMedGoogle Scholar
  • 28 The RAPT Investigators. Randomized trial of Ridogrel, a combined thromboxane A2, synthetase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction
    PubMedGoogle Scholar
  • 29 Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemostas 1994; 72 (03) 381-386
    PubMedGoogle Scholar
  • 30 Phaneuf MD, Ozaki CK JM T, Loza JP, Quist WC, LoGerfo FW. Covalent linkage of streptokinase to recombinant hirudin: a novel thrombolytic agent with antithrombotic properties. Thromb Haemostas 1994; 71 (04) 481-487
    PubMedGoogle Scholar
  • 31 Samama M. Laboratory control of thrombolytic treatment of myocardial infarction with rt-PA. Fibrinolysis 1993; 7 (01) 46-47
    PubMedGoogle Scholar
  • 32 Acar J, Dorent R, Vahanian A, Michel PL, Cormier B, Slama M, Cazaux P, Conard J, Verdy E, Samama M. Le risque hemorragique dans les traitements thrombolytiques par voie intraveineuse dans Tinfarctus myocardique aigu. Arch Mai Coeur 1988; 81 (01) 59-65
    PubMedGoogle Scholar
  • 33 Tracy RP, Bovill EG. Fibrinolytic parameters and hemostatic monitoring: identifying and predicting patients at risk for major hemorrhag ic events. Am J Cardiol 1992; 69: 52-59 A
    CrossrefPubMedGoogle Scholar
  • 34 Sobel BE. Intracranial bleeding, fibrinolysis and anticoagulation. Causal connections and clinical implications. Circulation 1994; 90 (04) 2147-2152
    CrossrefPubMedGoogle Scholar
  • 35 Sane DC, Califf RM. Complications of thrombolytic therapy. In: Thrombolysis and adjunctive therapy for acute myocardial infarction. Bates ER. ed. Marcel Dekker Inc; New York, Basel, Hong-Kong: 1944: 91-115
    Google Scholar
  • 36 Kase CS, O’Neal Am, Fischer M, Girgis GN, Ordia JI. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Intern Med 1990; 112: 17-21
    CrossrefPubMedGoogle Scholar
  • 37 Proner J, Rosenblum BR, Rothman A. Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator. Arch Neurol 1990; 47: 105-106
    CrossrefPubMedGoogle Scholar
  • 38 Harrington RA, Sane DC, Califf RM, Sigmon KN, Abbottsmith CW, Candela RJ, Lee K. Topol EJ for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Clinical importance of thrombocytopenia occuring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction J Am Coll Cardiol 1994; 23: 891-898
    CrossrefPubMedGoogle Scholar
  • 39 Melandri G, Branzi A, Traini AM, Semprini F, Cervi V, Magnani B. On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes. Am J Cardiol 1993; 71: 469-471
    CrossrefPubMedGoogle Scholar
  • 40 Samama M, Horellou MH, Laaban JP, Conard J. Should thrombolytic therapy be used in pulmonary embolism. In: Fundamental and Clinical Fibrinolysis. Castellino FJ, Gaffney PJ, Samama MM, Takada A. Eds. Excerpta Medica; Amsterdam: 1987. 757 215-226
    Google Scholar
  • 41 Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism. Chest 1992; 101 suppl (Suppl. 04) 183S-185S
    CrossrefPubMedGoogle Scholar
  • 42 Goldhaber SZ. Role of echocardiography in diagnosing and treating pulmonary embolism. Proc Congr Angio Geneve’94 1994; abst 02-08 103
    PubMedGoogle Scholar
  • 43 Goldhaber SZ, Sors H. Treatment of venous thrombosis and pulmonary embolism. In: Thrombosis in cardiovascular disorders. Fuster VF, Verstraete M, Saunders WB. Eds Philadelphia: 1992: 465-483
    Google Scholar
  • 44 Wardlaw JM, Warlow CP. Thrombolysis in acute ischemic stroke: does it work. Stroke 1992; 23: 1826-1839
    CrossrefPubMedGoogle Scholar
  • 45 del Zoppo GJ. Thrombolytic therapy in stroke. In: Thrombolysis yearbook. Agnelli G. Ed. Excerpta Medica, Amsterdam: 1994: 113-135
    Google Scholar
  • 46 Hommel M, Boissel JP, Comu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P. Bogaert M for the MAST Study Group. Termination of trial of streptokinase in severe acute ischaemic stroke Lancet 1994; 345: 57-57
    PubMedGoogle Scholar